Infliximab aggregates produced in severe and mild elevated temperature stress conditions induce an extended specific CD4 T-cell response - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Pharmaceutical Sciences Année : 2024

Infliximab aggregates produced in severe and mild elevated temperature stress conditions induce an extended specific CD4 T-cell response

Résumé

Aggregation has been widely described as a factor contributing to therapeutic antibody immunogenicity. Although production of high-affinity anti-drug antibodies depends on the activation of CD4 T lymphocytes, little is known about the T-cell response induced by antibody aggregates, especially for aggregates produced in mild conditions resulting from minor handling errors of vials. Large insoluble infliximab (IFX) aggregates produced in severe elevated temperature stress conditions have been previously shown to induce human monocyte-derived dendritic cell (moDC) maturation. We here showed that large IFX aggregates recruit in vitro a significantly higher number of CD4 T-cells compared to native IFX. Moreover, a larger array of T-cell epitopes encompassing the entire variable regions was evidenced compared to the native antibody. We then compared the responses of moDCs to different types of aggregates generated by submitting IFX to mild conditions of various times of incubation at an elevated temperature. Decreasing stress duration reduced aggregate size and quantity, and subsequently altered moDC activation. Of importance, IFX aggregates generated in mild conditions and not altering moDC phenotype generated an in vitro T-cell response with a higher frequency of CD4 T cells compared to native IFX. Moreover, cross-reactivity studies of aggregate-specific T cells showed that some T cells could recognize both native and aggregated IFX, while others responded only to IFX aggregates. Taken together, our results suggest that aggregation of antibodies in mild elevated temperature stress conditions is sufficient to alter moDC phenotype in a dose-dependent manner and to increase T-cell response

Domaines

Immunologie
Fichier principal
Vignette du fichier
1-s2.0-S0928098723002981-main.pdf (3.72 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04456640 , version 1 (20-02-2024)

Licence

Identifiants

Citer

Myriam Nabhan, Sylvain Meunier, Victor Le-Minh, Baptiste Robin, Marie de Bourayne, et al.. Infliximab aggregates produced in severe and mild elevated temperature stress conditions induce an extended specific CD4 T-cell response. European Journal of Pharmaceutical Sciences, 2024, 192, pp.106670. ⟨10.1016/j.ejps.2023.106670⟩. ⟨hal-04456640⟩
46 Consultations
17 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More